| Assessment of molecular relapse detection in early-stage breast cancer I Garcia-Murillas, N Chopra, I Comino-Méndez, M Beaney, H Tovey, ... JAMA oncology 5 (10), 1473-1478, 2019 | 284 | 2019 |
| ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the … NC Turner, C Swift, L Kilburn, C Fribbens, M Beaney, I Garcia-Murillas, ... Clinical Cancer Research 26 (19), 5172-5177, 2020 | 108 | 2020 |
| Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant … M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, ... Annals of oncology 32 (4), 488-499, 2021 | 95 | 2021 |
| Genomic profile of advanced breast cancer in circulating tumour DNA B Kingston, RJ Cutts, H Bye, M Beaney, G Walsh-Crestani, S Hrebien, ... Nature communications 12 (1), 2423, 2021 | 68 | 2021 |
| Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate-and … NC Turner, C Swift, B Jenkins, L Kilburn, M Coakley, M Beaney, L Fox, ... Annals of Oncology 34 (2), 200-211, 2023 | 48 | 2023 |
| Abstract GS3-06: Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in … N Turner, C Swift, B Jenkins, L Kilburn, M Coakley, M Beaney, L Fox, ... Cancer Research 82 (4_Supplement), GS3-06-GS3-06, 2022 | 21 | 2022 |
| Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer M Dowsett, L Kilburn, MF Rimawi, CK Osborne, K Pogue-Geile, Y Liu, ... Clinical Cancer Research 28 (1), 163-174, 2022 | 14 | 2022 |
| Microscopic gastrointestinal stromal tumours: a clinical and molecular study of 13 cases W Anderson, B O'Sullivan, F Hughes, C Swift, M Smith, N Deshmukh, ... Histopathology 70 (2), 211-216, 2017 | 13 | 2017 |
| Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial B Kingston, H Bye, M Hubank, G Walsh, C Swift, M Beaney, L Kilburn, ... Cancer Research 80 (4_Supplement), GS3-07-GS3-07, 2020 | 6 | 2020 |
| Abstract PD2-04: Baseline circulating ESR1 mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone … N Turner, C Swift, L Kilburn, I Garcia-Murillas, S Johnston, A Budzar, ... Cancer Research 79 (4_Supplement), PD2-04-PD2-04, 2019 | 4 | 2019 |
| Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients J Pascual, M Gil-Gil, P Proszek, C Zielinski, A Reay, M Ruiz-Borrego, ... Clinical Cancer Research 29 (20), 4166-4177, 2023 | 3 | 2023 |
| Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with … M Martin, C Zielinski, M Ruiz-Borrego, EM Carrasco, E Ciruelos, M Muñoz, ... Journal of Clinical Oncology 38 (15_suppl), 1022-1022, 2020 | 3 | 2020 |
| Baseline circulating ESR1 mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer N Turner, C Swift, L Kilburn, I Garcia-Murillas, S Johnston, A Budzar, ... Proceedings of the 2018 San Antonio Breast Cancer Symposium, 2018 December 4 …, 2019 | 3 | 2019 |
| Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple … M Coakley, P Sritharan, G Villacampa, C Swift, K Dunne, L Kilburn, ... Cancer Research 83 (5_Supplement), PD5-03-PD5-03, 2023 | 2 | 2023 |
| Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL+ FUL) versus capecitabine (CAPE). J Pascual, M Martin, P Proszek, M Gil-Gil, A Reay, C Zielinski, J Herranz, ... Journal of Clinical Oncology 40 (16_suppl), 1019-1019, 2022 | 1 | 2022 |
| CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. J Pascual, M Gil-Gil, C Zielinski, M Hills, M Ruiz-Borrego, EM Ciruelos, ... Journal of Clinical Oncology 39 (15_suppl), 1014-1014, 2021 | 1 | 2021 |
| Abstract PO1-04-10: Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial M Alva, S López-Tarruella, C Zielinski, M Ruíz-Borrego, N Turner, ... Cancer Research 84 (9_Supplement), PO1-04-10-PO1-04-10, 2024 | | 2024 |
| Tracking triple negative breast cancer (TNBC) evolution in the molecular residual disease (MRD) setting in the c-TRAK TN clinical trial M Coakley, RJ Cutts, P Sritharan, S Hrebien, C Swift, K Dunne, L Kilburn, ... Cancer Research 84 (6_Supplement), 3781-3781, 2024 | | 2024 |
| Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer M Coakley, G Villacampa, P Sritharan, C Swift, K Dunne, L Kilburn, ... Clinical Cancer Research 30 (4), 895-903, 2024 | | 2024 |
| Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA … N Turner, ER Phillips, C Bunce, M Robert, C Bailleux, I Garcia-Murillas, ... Cancer Research 83 (5_Supplement), OT1-01-01-OT1-01-01, 2023 | | 2023 |
